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Abstract
Purpose Sodium oxybate (SXB) is approved for cataplexy
and excessive daytime sleepiness in narcolepsy. Obstructive
sleep apnea syndrome (OSAS) affects ∼9–50% of narco-
leptics. Effects of 2-week SXB administration on apnea–
hypopnea index (AHI), oxygen saturation (SaO2), and sleep
architecture were investigated in OSAS patients.
Methods OSAS patients (n=48) received 2-week SXB or
placebo (PBO) treatment with polysomnography at baseline
and day 14. The primary outcome measure was change
from baseline in mean AHI. Secondary outcomes included
changes from baseline in SaO2, and sleep architecture.
Results Compared with PBO, SXB significantly increased
reduction in mean AHI and obstructive apnea index with
SXB (−0.8±13.3 vs. −8.2±10.0; p=0.0327 and 3.54±11.1
vs. −4.72±7.7; p=0.0054, respectively) and significantly
increased change in slow wave sleep duration (5.2±
25.0 min vs. 29.4±37.0 min; p=0.0038). There were no
differences between treatments in SaO2, central apneic
events, or other measures. Adverse events, most commonly
headache, were noted in nine of 27 (33%) and six of 23
(26%) patients receiving SXB and PBO, respectively.
Conclusions Short-term use of 4.5 g/night SXB did not
generate respiratory depressant effects in OSAS patients as
measured by AHI, obstructive apnea events, central apneas,
and SaO2. Extended use of SXB in higher therapeutic
doses in OSAS has not been studied, and merits caution.
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Introduction
Sodium oxybate (SXB), the sodium salt of gamma-
hydroxybutyrate (GHB), was developed in France by Henri
Laborit in 1960 and was initially used as an adjunct
anesthetic agent [1, 2]. Since then, it has been developed
for the treatment of narcolepsy and is approved in the USA
for the treatment of excessive daytime sleepiness and
cataplexy in narcolepsy and for narcolepsy and cataplexy
in the European Union and Canada. It is also approved in
Germany for intravenous anesthesia and in Italy and
Austria for the treatment of alcoholism. Reports of efficacy
of SXB in the treatment of fibromyalgia [3] have led to
development of a phase III program. The effects of SXB on
sleep architecture [4–6] and improvement of cataplexy and
excessive daytime sleepiness (EDS) in narcolepsy [7–10]
are well documented; however, its precise mechanism of
action remains unknown. The continuous improvement in
cataplexy observed over 6–12 months of narcolepsy
treatment suggests durable effects of SXB therapy that
might be mediated via long-term neuroplastic changes [8].
There are conflicting reports on the effects of SXB on
respiration during sleep. Studies with GHB have demon-
strated significant central nervous system depression with-
out respiratory depression [1, 11]; however, there have been
reports of respiratory depression with GHB abuse often in
the presence of cointoxicants such as alcohol [12], and
respiratory depression was reported during clinical trials
with SXB in narcolepsy [4, 13].
Although the incidence of co-occurring obstructive sleep
apnea syndrome (OSAS) in narcolepsy patients has not
been well studied, estimates range from 9–50% [13–15].
The incidence of OSAS in narcolepsy may be related to an
association between the high risk of OSAS with obesity
[16–18], the higher body-mass-index found in narcoleptics
compared with the general population, and binge-eating
seen in childhood-onset narcolepsy [19, 20].
Significant concern regarding the effects of long-term use
of SXB on sleep disordered breathing in narcoleptic patients
with co-occurring OSAS remains despite no demonstrable
acute effects of SXB on mean apnea–hypopnea index (AHI)
or SaO2 [21]. In the continuation phase of the previously
reported study [21], the effects of administration of an
additional two weeks of outpatient SXB on AHI and other
measures of sleep disordered breathing (SDB), sleep
architecture, and EDS are described here.
Methods
Subjects
Sixty patients with OSAS were recruited from two centers
(St. Petersburg, FL and London, Ontario, Canada). Inclu-
sion criteria included a history of OSAS, AHI ≥10 and ≤40,
and SaO2 nadir ≥75% (AASM Task Force 1999 criteria for
OSAS [23]). Exclusion criteria included a recent history of
substance abuse or shift work, or experiencing any major
illness, including unstable cardiovascular, endocrine, neo-
plastic, gastrointestinal, hematologic, hepatic, immunologic,
metabolic, neurological, pulmonary, and/or renal disease.
Sixteen patients were using continuous positive airway
pressure (CPAP) prior to screening and discontinued use
during the study. Patients were withdrawn from the study if
they failed to comply with the protocol or had any serious
adverse events (AEs).
Study design
Following screening, patients had one baseline overnight
polysomnography (PSG). This allowed the participants to
acclimatize to the laboratory and ensured that the inclusion
criteria were met. During this baseline PSG, ten patients
experienced oxygen desaturation below 75% lasting less
than 10 s. These were judged by the investigators to be
artifacts and the patients continued in the study. Prior to
entering the 2-week randomized outpatient continuation
phase reported here, patients received the following four
treatments in a crossover design on four consecutive nights:
(1) 9 g SXB, (2) 9 g sodium oxybate/modafinil 200 mg
(SXB/MOD), (3) Zolpidem 10 mg (ZOL), and (4) placebo
(PBO). These results are reported elsewhere [21].
Following the end of the acute phase, patients were
randomizedtooneoftwotreatmentgroups:(1)SXB:Xyrem®
500 mg/ml oral solution, Jazz Pharmaceuticals, Inc. in a dose
o f4 . 5gp e rn i g h tf o r1 3d a y sa n d9gf o rd a y1 4( t a k e ni n
divided doses at bedtime and 2.5–4 h after their first dose) or
(2) placebo (sodium citrate solution, equimolar to Xyrem®
with respect to sodium and indistinguishable by taste, Jazz
Pharmaceuticals, data on file), taken in divided doses at
bedtime and 2.5–4 h after their first dose. A lower dose of
SXB was administered in the outpatient setting (4.5 g) due to
the potential risk of respiratory depression in the unmonitored
home setting. To provide a more relevant evaluation of
potential SXB-induced risk, sleep breathing events and sleep
architecture were studied using the highest approved dose of
SXB (9 g) in subjects who had become accustomed to
receiving a lower dose at home. Eight patients in each group
used CPAP during the outpatient phase of the study and none
used CPAP during the final PSG visit on day 14. The results
for the patients who used CPAP were not analyzed separately.
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The primary outcome variable was the change in mean AHI
from baseline to the final PSG visit on day 14. AHI was
defined as the number of apneas (obstructive, mixed, and
central) plus hypopneas per hour of sleep. Secondary
outcomes included the mean changes in sleep architecture,
oxygenation variables and Epworth Sleepiness Scale
(ESS) scores [22]. Events were defined using standard
criteria [23] and studies were manually scored by one
registered polysomnographic technologist. Criteria for
scoring hypopneas followed standard criteria of: (1) A
clear decrease (>50%) from baseline in the amplitude of a
valid measure of breathing during sleep. Baseline is defined
as the mean amplitude of stable breathing and oxygenation
in the two minutes preceding onset of the event (in
individuals who have a stable breathing pattern during
sleep) or the mean amplitude of the three largest breaths in
the 2 min preceding onset of the event (in individuals
without a stable breathing pattern); (2) A clear amplitude
reduction of a validated measure of breathing during sleep
that does not reach the above criterion but is associated
with either an oxygen desaturation of >3% or an arousal;
and (3) The event lasts 10 s or longer [23]. Sleep was
scored per Rechtschaffen and Kales criteria [24]. The data
were analyzed by the two-sample t test. If the normality
assumption was not met, Wilcoxon's rank-sum test was
used. A significance level of 0.05 was used. All tests were
two-sided. Due to the nonparametric nature of the data,
Spearman's rank-order correlation coefficients were com-
puted for changes in slow wave sleep (SWS; stages 3 and 4
nonrapid eye-movement sleep), AHI, and ESS. A correla-
tion was accepted as significant if the p value was <0.05;
the sign of the correlation coefficient indicates whether the
variable pairs positively or negatively correlated.
Ethics
The protocol used in this study was approved by the
Institutional Review Board/Ethics Board of each participating
trial center. Written informed consent was obtained from each
patient prior to initiation of the study. This study was
conducted in accordance with the Helsinki Declaration,
revised 1997. Clinical trial registry: ClinicalTrials.gov;
clinical trial registration number: NCT00086281.
Results
Demographics
Fifty patients (83%) were randomized and 48 (80%)
completed the outpatient phase of the trial (Fig. 1). Two
patients (4%) withdrew due to adverse events prior to
receiving any study drug. Demographic characteristics are
presented for all randomized patients in Table 1. There were
no differences between groups in mean age, weight, height,
BMI, race, or sex. Results are presented for patients who
completed the trial in Table 2.
Sleep disordered breathing
There were no differences in respiratory PSG measurements
between groups at baseline (see Table 1). The mean AHI
was significantly reduced from baseline in the SXB
treatment group compared with PBO at day 14 (−8.2±
10.0 vs. −0.8±13.3; p=0.0327). In addition, the number of
obstructive apneic events per hour (obstructive apnea
index) was also significantly reduced from baseline in the
SXB group compared with PBO (−4.72±7.68 vs. 3.54±
11.08; p=0.0054). There were no differences between
Fig. 1 Subject flow diagram
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hour. The proportion of patients at the final visit with an
AHI<10 for SXB was numerically greater than PBO (2/22
(9.1%) vs. 8/26 (30.8%)) and opposite trend was seen for
the proportion with SaO2 nadir <85% for SXB compared
with PBO (18/26 (69.2%) vs. 12/22 (54.6%); however,
these differences were not statistically significant.
Sleep architecture
As shown in Table 1, there were no differences in sleep
architecture characteristics between groups at baseline.
There was an increased duration of SWS with SXB
treatment, which was significantly greater than the change
from baseline seen in PBO (29.4±37.0 min vs. 5.2±
25.0 min; p=0.0038). There were no differences between
groups in incremental changes in time spent in stage 1 or
stage 2 sleep, or rapid eye movement (REM) sleep, total
sleep time, wake after sleep onset, or arousal index.
Excessive daytime sleepiness
Epworth sleepiness scale scores decreased in both treatment
groups, but this difference was not significant (−3.5±5.3
with SXB vs. −0.6±3.3 with PBO; p=0.09).
Correlational analysis
As indicated in Fig. 2, the change from baseline in SWS
was negatively and significantly correlated with the change
from baseline in AHI for all patients (r=−0.38; p=0.0074)
but not for SXB (r=−0.252, ns) or PBO (r=−0.274, ns)
alone. No significant correlations between change from
baseline in SWS and either change in obstructive apneas or
ESS were seen.
Safety
Of the 50 patients who were randomized and for whom
AEs are reported in Table 3, two patients withdrew before
receiving drug in this study. These two patients reported
AEs at the end of the prior study which are reported
elsewhere [21]. No other patients withdrew during the
double-blind phase. As shown in Table 3, nine of 27
(33.0%) and 6/23 (26.1%) patients experienced AEs in the
SXB and PBO groups, respectively. The most common
individual event was headache (4/23 in PBO and 2/27 in
SXB). There were no serious AEs or deaths reported during
the study.
Discussion
There is a compelling clinical need to determine whether
therapeutic agents with the potential to cause respiratory
depression such as SXB can be safely used in patients with
OSAS, especially since CPAP treatment compliance is
generally poor, typically less than 50% in patients with
OSAS [25]. SXB is currently a standard treatment for
narcolepsy, where a potentially large proportion (9–50%) of
patients may also have diagnosed or undetected OSAS
[13, 15, 16]. Patients with OSAS have compromised
respiration during sleep due to an increased mechanical
load on the airway combined with the normal decrease in
respiratory drive. In normal subjects, reduced facilitatory
drive to the upper respiratory muscles occurs as sleep
progresses through deeper stages of sleep (stages 1–4) and
then to REM. This reduced drive is accompanied by
decreases in minute ventilation and ventilatory drive and
lung volumes, leading to increased upper airway resistance
and increased respiratory events [26].
Characteristic Placebo (n=23), mean (SD) SXB (n=27), mean (SD)
Age (years) 49.7 (11.1) 49.7 (8.0)
Weight (kg) 100.7 (16.6) 102.7 (18.3)
Height (cm) 174.7 (4.5) 175.9 (9.7)
BMI (kg/m
2) 33.0 (5.4) 33.2 (5.0)
Race—counts (%)
Caucasian 21 (91.3) 24 (88.9)
Black 1 (4.3) 2 (7.4)
Asian 1(4.3) 0 (0)
Hispanic 0 (0) 1 (3.7)
Other 0 (0) 0 (0)
Sex—counts (%)
Male 20 (87) 21 (77.8)
Female 3 (13) 6 (22.2)
Table 1 Study demographics
SXB sodium oxybate, BMI body
mass index
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SXB in mild to moderate OSAS demonstrated that SXB
4.5 g in two divided doses nightly over 13 nights followed
by a final night of 9 g challenge did not increase the risk of
respiratory depression. Instead, compared with baseline
PSG values obtained prior to the crossover phase of the
study, an improvement in AHI and a reduction in the
number of obstructive apnea events were seen at day 14
with 9 g SXB treatment. These results are similar to other
trials of SXB which demonstrated a decrease in duration
of obstructive apneas and increased SWS and no
worsening of AHI in doses of approximately 4–9 g nightly
[27–29].
Limitations of this study
Interpretation of these results are limited both by the small
sample size (n=50) and the analysis of only one final PSG
night with SXB treatment. Although an overall decrease of
AHI with SXB treatment was demonstrated, significant
Table 2 Treatment effects of SXB on SDB and sleep architecture
Baseline Night 14
PBO (n=22) SXB (n=26) p value PBO (n=22) SXB (n=26) p value
Respiratory parameters—mean (SD)
AHI 25.0 (8.1) 23.5 (10.0) NS 24.2 (13.9) 15.3 (8.5)
AHI Change from baseline −0.79 (13.3) −8.2 (10.0) 0.0327
Central Apneas Index 0.55 (1.34) 0.68 (1.84) NS 0.74 (1.52) 1.20 (2.30)
Central Apneas Index Change from baseline 0.19 (0.69) 0.51 (1.09) NS
Obstructive Apneas Index 7.62 (7.79) 9.02 (9.94) NS 11.16 (10.72) 4.30 (4.40)
Obstructive Apneas Index Change from baseline 3.54 (11.08) −4.72 (7.68) 0.0054
SaO2 (Mean) 95.3 (1.2) 94.6 (1.6) NS 94.9 (1.5) 94.6 (1.6)
SaO2 (Mean) Change from baseline −0.4 (1.6) 0.1 (2.0) NS
SaO2 < 90% (in min) 1.0 (1.2) 1.5 (2.2) NS 1.4 (1.5) 1.6 (2.0)
SaO2 < 90% (in min), change from baseline 0.5 (1.5) 0.1 (2.7) NS
SaO2 < 80% (in min) 0.02 (0.04) 0.04 (0.12) NS 0.2 (0.6) 0.1 (0.3)
SaO2 < 80% (in min) Change from baseline 0.2 (0.6) 0.1 (0.3) NS
Sleep Architecture (min)—Mean (SD)
Stage 1 19.5 (10.9) 15.7 (11.7) NS 10.2 (6.5) 8.7 (8.4)
Stage 1 Change from baseline −9.3 (11.0) −7.0 (12.0) NS
Stage 2 233.5 (54.6) 240.5 (44.8) NS 254.8 (55.2) 265.6 (34.5)
Stage 2 Change from baseline 21.3 (43.3) 25.1 (52.4) NS
SWS (Stage 3&4) 37.5 (25.4) 43.7 (19.8) NS 42.7 (24.4) 73.1 (40.0)
SWS Change from baseline 5.2 (25.0) 29.4 (37.0) 0.0038
REM Sleep 73.6 (28.3) 74.7 (27.6) NS 84.2 (28.8) 71.3 (30.4)
REM Sleep Change from baseline 10.6 (26.0) −3.4 (39.2) NS
WASO 98.7 (66.3) 91.1 (66.2) NS 80.8 (58.3) 56.8 (25.5)
WASO Change from baseline −18.0 (49.3) −34.3 (65.0) NS
TST 364.2 (65.8) 374.7 (65.5) NS 392.0 (55.9) 424.5 (31.9)
TST Change from baseline 27.8 (55.8) 49.8 (64.6) NS
Arousal index (n/hr) 4.5 (7.0) 2.4 (3.6) NS 4.9 (10.3) 1.5 (2.7)
Arousal index Change from baseline 0.4 (5.6) −0.8 (4.2) NS
Epworth Sleepiness Score
ESS 11 (5.8) 12.2 (5.1) NS 10.5 (6.6) 8.6 (4.8)
ESS Change from baseline −0.6 (3.3) −3.5 (5.3) NS
SXB=sodium oxybate; PBO=placebo; AHI=apnea-hypopnea index; SaO2=oxygen saturation; SWS=slow wave sleep; REM=rapid eye
movement; WASO=wake after sleep onset; TST=total sleep time; ESS=Epworth Sleepiness Scale
Sleep Breath (2011) 15:13–20 17night-to-night variability in AHI has been noted in the
literature [30–32]. Furthermore, the dosing scheme of SXB
9 g on the night of the final attended PSG and 4.5 g for
2 weeks at home was chosen to maximize patient safety but
may not accurately reflect the long-term effects of SXB on
sleep disordered breathing.
Methodological issues such as the choice of baseline
PSG values prior to the crossover phase of the study instead
System Organ Class Preferred term Placebo (n=23) Sodium oxybate (n=27)
N (%) N (%)
Number of patients with any event 6 (26.1) 9 (33.3)
Eye disorders 1 (4.3) 0 (0)
Asthenopia 1 (4.3) 0 (0)
Eye pain 1 (4.3) 0 (0)
Vision blurred 0 (0) 1 (3.7)
Gastrointestinal disorders 0 (0) 1 (3.7)
Dyspepsia 0 (0) 1 (3.7)
Diarrhea 0 (0) 1 (3.7)
General disorders and administration site conditions 1 (4.3) 0 (0)
Fatigue 1 (4.3) 0 (0)
Infections and infestations 1 (4.3) 0 (0)
Bronchitis 1 (4.3) 0 (0)
Injury, poisoning, and procedural complications 0 (0) 1 (3.7)
Limb injury 0 (0) 1 (3.7)
Musculoskeletal and connective tissue disorders 1 (4.3) 1 (3.7)
Musculoskeletal stiffness 1 (4.3) 0 (0)
Rotator cuff syndrome 0 (0) 1 (3.7)
Nervous system disorders 4 (17.4) 3 (11.1)
Dizziness 0 (0) 1 (3.7)
Headache 4 (17.4) 2 (7.4)
Somnolence 1 (4.3) 0 (0)
Respiratory, thoracic, and mediastinal disorders 2 (8.7) 1 (3.7)
Dry throat 1 (4.3) 0 (0)
Epistaxis 1 (4.3) 0 (0)
Pharyngolaryngeal pain 0 (0) 1 (3.7)
Skin and subcutaneous disorders 0 (0) 1 (3.7)
Pruritis generalized 0 (0) 1 (3.7)
Table 3 Summary of
treatment-related post-dose
adverse events (MedDRA
classification)
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Fig. 2 Correlation analysis
of SWS and AHI. The change
from baseline in SWS was
negatively correlated with the
change from baseline in AHI
for all patients (r=−0.38;
p=0.0074) but not for
SXB (r=−0.252, ns) or
PBO (r=−0.274, ns) alone
18 Sleep Breath (2011) 15:13–20of following the crossover phase may not accurately reflect
the true baseline values. Also, the effects of SXB seen in
the present study in OSAS patient may differ from those in
narcoleptic patients with concurrent OSAS.
Conclusion
It is not clear how SXB might reduce AHI in OSAS
patients. Overall, the change from baseline in mean SWS
was associated with the change in mean AHI for the whole
sample studied but not for the SXB or PBO group alone.
This is most likely due to smaller numbers in the individual
groups. It is not clear if the increment of SWS is
mechanistically associated with improvement of AHI. It is
speculated that SXB may affectbrainstem catecholaminergic
systems [33] that may increase the facilitatory drive to
stabilize the upper airway. SXB may also have additional
more direct effects on muscle tone, as GHB administration-
induced increased peripheral muscle EMG activity has been
reported in animal studies [34].
The presence of sleep disordered breathing should be
carefully evaluated in all patients who are candidates for
SXB therapy. As indicated in the crossover study, nighttime
administration of SXB 9 g resulted in more central apneas
than PBO [21]. Therefore, further studies investigating the
longer-term effects (>3 months) of higher doses of SXB (6
to 9 g) on sleep disordered breathing as well as studies
investigating the respiratory effects of SXB on CPAP com-
pliance and pressures in patients with co-occurring OSAS are
recommended.
Short-term use of SXB at 4.5 g per night did not
generate respiratory depressant effects in patients with
OSAS as measured by AHI, obstructive apnea events,
central apneas, and SaO2. The effects of longer term use of
SXB in higher therapeutic doses for patients with OSAS
have not been rigorously studied and nocturnal oximetry
monitoring or nocturnal polysomnography with SXB might
be useful. SXB therapy in patients with co-occurring OSAS
should be approached with caution.
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